应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
COAG Hemab Therapeutics Holdings, Inc.
交易中 11-20 14:22:23 EST
39.06
-0.80
-2.01%
最高
40.19
最低
38.77
成交量
16.68万
今开
39.50
昨收
39.86
日振幅
3.56%
总市值
18.24亿
流通市值
6.54亿
总股本
4,671万
成交额
659.22万
换手率
1.00%
流通股本
1,675万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Hemab Therapeutics宣布Hmb-003治疗重度月经出血的1期临床试验首例受试者完成给药
美股速递 · 09-17
Hemab Therapeutics宣布Hmb-003治疗重度月经出血的1期临床试验首例受试者完成给药
H.C. Wainwright 首次覆盖 Hemab Therapeutics,给予“买入”评级及40美元目标价
美股速递 · 06-17
H.C. Wainwright 首次覆盖 Hemab Therapeutics,给予“买入”评级及40美元目标价
公司概况
公司名称:
Hemab Therapeutics Holdings, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Hemab Therapeutics Holdings, Inc.于2026年2月12日根据特拉华州法律注册成立。Hemab Therapeutics是一家临床阶段的生物技术公司,致力于开发革新血液凝固障碍治疗的疗法,以帮助维持生命并增强人类的抵抗力。公司的使命是通过发现、开发和商业化创新疗法,为全球患有严重出血和血栓性疾病的患者打造领先的凝血领域公司。这些疾病包括格氏血小板无力症、VII因子缺乏症、血管性血友病以及其他可能造成终身沉重负担的异常出血性疾病。公司的主要候选药物sutacimig (HMB-001) 是一种双特异性抗体,目前正在进行一项针对格氏血小板无力症预防性治疗的I/II期临床试验和一项针对VII因子缺乏症预防性治疗的II期临床试验。
发行价格:
--
{"stockData":{"symbol":"COAG","market":"US","secType":"STK","nameCN":"Hemab Therapeutics Holdings, Inc.","latestPrice":39.06,"timestamp":1795202533734,"preClose":39.86,"halted":0,"volume":166801,"delay":0,"changeRate":-0.02007024586051172,"floatShares":16750000,"shares":46705400,"eps":-2.001,"marketStatus":"交易中","change":-0.8,"latestTime":"11-20 14:22:23 EST","open":39.5,"high":40.19,"low":38.77,"amount":6592180.685230001,"amplitude":0.035625,"askPrice":39.19,"askSize":300,"bidPrice":38.97,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-2.001,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1795208400000},"marketStatusCode":2,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":39.86,"preHourTrading":{"tag":"盘前","latestPrice":39.52,"preClose":39.86,"latestTime":"09:29 EST","volume":2600,"amount":103952.004,"timestamp":1795184996066,"change":-0.34,"changeRate":-0.00853,"amplitude":0.012042},"postHourTrading":{"tag":"盘后","latestPrice":39.86,"preClose":39.86,"latestTime":"19:31 EST","volume":1512,"amount":60274.22,"timestamp":1795134715213,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.674485},"requestUrl":"/m/hq/s/COAG/wiki","defaultTab":"wiki","newsList":[{"id":"1199925896","title":"Hemab Therapeutics宣布Hmb-003治疗重度月经出血的1期临床试验首例受试者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1199925896","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199925896?lang=zh_cn&edition=full","pubTime":"2026-09-17 20:01","pubTimestamp":1789646470,"startTime":"0","endTime":"0","summary":"Hemab Therapeutics今日宣布,其用于管理重度月经出血的在研疗法Hmb-003,已在1期临床试验中完成首例受试者给药。这一里程碑标志着该候选药物正式进入人体临床评估阶段。\nHmb-003是一种新型 investigational 疗法,旨在为饱受重度月经出血困扰的患者提供更优的治疗选择。此次1期试验的主要目标在于评估药物的安全性、耐受性及药代动力学特征,为进一步的临床开发奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","COAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183732399","title":"H.C. Wainwright 首次覆盖 Hemab Therapeutics,给予“买入”评级及40美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1183732399","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183732399?lang=zh_cn&edition=full","pubTime":"2026-06-17 18:08","pubTimestamp":1781690902,"startTime":"0","endTime":"0","summary":"投资机构 H.C. Wainwright 近日启动了对 Hemab Therapeutics Holdings, Inc. 的研究覆盖,并给予了“买入”评级。该机构为这家生物技术公司设定了每股40美元的目标价格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","COAG"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hemab.com","stockEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.1665},{"period":"3month","weight":-0.1892},{"period":"6month","weight":0.5396},{"period":"1year","weight":1.2144},{"period":"ytd","weight":1.2144}],"compareEarnings":[{"period":"1week","weight":-0.0545},{"period":"1month","weight":-0.0692},{"period":"3month","weight":-0.0651},{"period":"6month","weight":-0.0399},{"period":"1year","weight":0.0803},{"period":"ytd","weight":0.0498}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Hemab Therapeutics Holdings, Inc.于2026年2月12日根据特拉华州法律注册成立。Hemab Therapeutics是一家临床阶段的生物技术公司,致力于开发革新血液凝固障碍治疗的疗法,以帮助维持生命并增强人类的抵抗力。公司的使命是通过发现、开发和商业化创新疗法,为全球患有严重出血和血栓性疾病的患者打造领先的凝血领域公司。这些疾病包括格氏血小板无力症、VII因子缺乏症、血管性血友病以及其他可能造成终身沉重负担的异常出血性疾病。公司的主要候选药物sutacimig (HMB-001) 是一种双特异性抗体,目前正在进行一项针对格氏血小板无力症预防性治疗的I/II期临床试验和一项针对VII因子缺乏症预防性治疗的II期临床试验。","exchange":"NASDAQ","name":"Hemab Therapeutics Holdings, Inc.","nameEN":"Hemab Therapeutics Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Hemab Therapeutics Holdings, Inc.(COAG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Hemab Therapeutics Holdings, Inc.(COAG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Hemab Therapeutics Holdings, Inc.,COAG,Hemab Therapeutics Holdings, Inc.股票,Hemab Therapeutics Holdings, Inc.股票老虎,Hemab Therapeutics Holdings, Inc.股票老虎国际,Hemab Therapeutics Holdings, Inc.行情,Hemab Therapeutics Holdings, Inc.股票行情,Hemab Therapeutics Holdings, Inc.股价,Hemab Therapeutics Holdings, Inc.股市,Hemab Therapeutics Holdings, Inc.股票价格,Hemab Therapeutics Holdings, Inc.股票交易,Hemab Therapeutics Holdings, Inc.股票购买,Hemab Therapeutics Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Hemab Therapeutics Holdings, Inc.(COAG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Hemab Therapeutics Holdings, Inc.(COAG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}